Mission Bio’s Tapestri Platform Unveils Insights into Targeted Therapy and Residual Disease Assessment for Multiple Myeloma

​​SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, announced a new publication led by Hervé Avet-Loiseau, MD, PhD, revealing new insights into disease progression of multiple myeloma (MM). Using Mission Bio’s single-cell DNA sequencing Tapestri® Platform, the study shows that solely targeting the RAS/RAF pathway for therapeutic intervention or residual disease assessment for MM may not be a viable approach due to th
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks